Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Morgan Stanley analyst Chris Quintero raised the firm’s price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares. The firm has greater conviction in Vertex being a ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Analyst Joshua Reilly of Needham maintained a Buy rating on Vertex (VERX – Research Report), boosting the price target to $60.00. Joshua ...

KING OF PRUSSIA, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology ...

SCOTT, La., Oct. 31, 2024 /PRNewswire/ -- Gordon Technologies LLC ("Gordon"), an Enersol company, has acquired Vertex Downhole Trading LLC ("Vertex UAE"), which is the Eastern Hemisphere business of ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.00% to $475.08 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.33% ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.26% to $470.36 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.16% ...